Author + information
- Sameer Dani1,
- Prathapkumar Natarajapillai2,
- Apurva Vasavada3,
- Jayachandran Thejus2,
- Pritesh Parekh4,
- Kamal Sharma1,
- Rutvik Trivedi5,
- Nirav Bhalani6,
- Arvind Sharma6 and
- Chirag Sheth6
In the recent era, stent implantation has become the treatment of choice among patients with Coronary Artery disease. We aimed to examine the safety and efficacy of Abluminus® DES+, Novel Abluminal Coated Sirolimus Eluting Stent coated on stent and parts of a balloon in real-world patients with coronary artery disease.
The study is prospective, multi-centre and enrolled patients from a real world. The principle endpoints were Major Adverse Cardiac Events (MACE) composite of cardiac death, Target vessel myocardial infarction (TV-MI), or Target lesion/vessel revascularization (TLR/TVR) and Stent thrombosis (ST) within 2 years. ST was defined as per ARC.
A total of 1,841 patients with 2,172 lesions were treated with 2,387 Abluminus® DES+ stents. Total Population of the study was predominated by male patients (79.52%). 37.05% patients presented with Diabetes and 44.98% patients presented with Hypertension. Acute Myocardial Infarction accounted for 34% of the patients. The majority of the lesions were sited in a left anterior descending artery (49.13%). 1-year follow-up was available in 82.78 % patients and MACE rate was 2.36%. Total 59.58% patients completed 2 years follow-up and MACE were 3.37% mainly driven by TLR/TVR (2.46%), TV-MI (0.55%) and cardiac death (0.36%). ST was reported as 0.66% for 1 year. There was no increment of MACE at 2 years.
Long-term clinical outcomes of ABLUMINUS® DES+ in “Real World” population demonstrated good performance, efficacy, and safety up to two years, with no late or very late stent thrombosis.